RAPIGEL

Main information

  • Trade name:
  • RAPIGEL MUSCLE AND JOINT RELIEVING GEL
  • Pharmaceutical form:
  • TOPICAL CREAM, OINTMENT, PASTE, GEL, LOTION
  • Units in package:
  • 250g
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • RAPIGEL MUSCLE AND JOINT RELIEVING GEL
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • DOG | HORSE | BITCH | CASTRATE | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH PERFORMANCE HORSES | HORSES AT
  • Therapeutic area:
  • counterirritant
  • Therapeutic indications:
  • ANTI-INFLAMMATORY AGENT | RELIEVE MUSCLE SORENESS | ANTIPYRETIC | BONE SORENESS | BRUISING | BURSITIS | INFLAMMATORY RHEUMATIC ARTHRIT | JOINT DISEASE | LIGAMENT SPRAINS | MUSCLE SORENESS | OSTEOARTHRITIS | PLATELET ACTIVITY | RHEUMATISM | SPRAINS | STRAINS | TENDON SPRAINS | TRAUMATIC SWELLING
  • Product summary:
  • Aids in reducing inflammation and swelling in joints and tendons; relieves muscle soreness due to over exertion, fatigue or bruising; for use on horses and dogs.

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered and available
  • Authorization number:
  • 35731/56890
  • Authorization date:
  • 22-06-2012
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

Virbac (Australia) Pty Limited

Page

1 of 2

Product Name:

RAP1GEL Muscle and Joint Relieving Gel

APVMA No.:

35731

Text Labels:

Jar, Tube

Pack Sizes:

500 g, 250 g, 200 g, 1009

Version Date:

29-05-12

Approve c.)

READ SAFETY DIRECTIONS BEFORE OPENING OR USING

FOR ANIMAL TREATMENT ONLY

RAPIGEL

Muscle and Joint Relieving Gel

ACTIVE CONSTITUENTS:

Isopropyl Alcohol 350 mg/g, Menthol 20 mg/g, Camphor 6.25 mg/g

RARGEL aids in reducing inflammation and swelling in joints and tendons.

RAPIGEL relieves muscle soreness due to over exertion, fatigue and bruising.

RAPIGEL is for use on horses and dogs.

500 g, 250 g, 200 g, 100 g

DIRECTIONS FOR USE

RAPIGEL should be rubbed into affected area at full strength, before and after workout.

Use under wet or dry bandages.

MEAT WITHHOLDING PERIOD (HORSES): ZERO (0) DAYS.

SAFETY DIRECTIONS

Poisonous if swallowed. Will irritate the eyes. Avoid contact with eyes. If product in eyes

wash it out immediately with water. Wash hands after use.

FIRST AID

If poisoning occurs get to a doctor or hospital quickly. if swallowed, do NOT induce

vomiting. Give a glass of water. Avoid giving milk or oils.

Additional safety information: Avoid contact with open wounds and mucous

membranes.

DISPOSAL

Dispose of empty container by wrapping with paper and putting in garbage.

STORAGE

KEEP OUT OF REACH OF CHILDREN

Store below 30

C (Room Temperature) in a cool place. Keep the lid tightly closed.

Infopest

Verified

Virbac (Australia) Pty Limited

Page

2 of 2

Product Name:

RAPIGEL Muscle and Joint Relieving Get

APVMA No.:

35731

Text Labels:

Jar, Tube

Pack Sizes:

500 g, 250 g, 200 g, 100 g

Version Date:

29-05-12

Virbac (Australia) Pty Ltd.

361 Horsley Road,

Milperra NSW 2214, Australia

Freecall Customer Service Line: 1800 009 847

www.virbac.corn.au

® Registered Trademark of Virbac (Austrglia) Pty. Ltd.

APVMA:

35731/56890

Code No.: 1PXXXX - X

EXP:

<Virbac Logo>

<Barcode>

There are no safety alerts related to this product.

1-10-2018

EU/3/05/328 (Celgene Europe B.V.)

EU/3/05/328 (Celgene Europe B.V.)

EU/3/05/328 (Active substance: (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone) - Transfer of orphan designation - Commission Decision (2018)6434 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/056/05/T/03

Europe -DG Health and Food Safety

1-10-2018

EU/3/05/279 (Celgene Europe B.V.)

EU/3/05/279 (Celgene Europe B.V.)

EU/3/05/279 (Active substance: (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone) - Transfer of orphan designation - Commission Decision (2018)6433 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/001/05/T/03

Europe -DG Health and Food Safety